These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 36835130)

  • 21. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
    Bhattacharya S; Harris HL; Islam R; Bodas S; Polavaram N; Mishra J; Das D; Seshacharyulu P; Kalluchi A; Pal A; Kohli M; Lele SM; Muders M; Batra SK; Ghosh PM; Datta K; Rowley MJ; Dutta S
    Cell Death Dis; 2024 Aug; 15(8):617. PubMed ID: 39183332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
    DeLucia DC; Cardillo TM; Ang L; Labrecque MP; Zhang A; Hopkins JE; De Sarkar N; Coleman I; da Costa RMG; Corey E; True LD; Haffner MC; Schweizer MT; Morrissey C; Nelson PS; Lee JK
    Clin Cancer Res; 2021 Feb; 27(3):759-774. PubMed ID: 33199493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
    Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
    Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
    Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.
    Rajabi H; Ahmad R; Jin C; Joshi MD; Guha M; Alam M; Kharbanda S; Kufe D
    Prostate; 2012 Nov; 72(15):1659-68. PubMed ID: 22473899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
    Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
    Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
    Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC; Shen M; Aslan M; Liu S; Kumar M; Garcia-Marques F; Nguyen HM; Nolley R; Pitteri SJ; Corey E; Brooks JD; Stoyanova T
    Sci Rep; 2021 Jun; 11(1):13305. PubMed ID: 34172788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ASCL1-mediated ferroptosis resistance enhances the progress of castration-resistant prostate cancer to neurosecretory prostate cancer.
    Nie J; Zhang P; Liang C; Yu Y; Wang X
    Free Radic Biol Med; 2023 Aug; 205():318-331. PubMed ID: 37355053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.
    Bhattacharya A; Wang K; Penailillo J; Chan CN; Fushimi A; Yamashita N; Daimon T; Haratake N; Ozawa H; Nakashoji A; Shigeta K; Morimoto Y; Miyo M; Kufe DW
    Oncogene; 2024 Jul; 43(28):2199-2214. PubMed ID: 38802648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
    Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and management of neuroendocrine prostate cancer.
    de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
    Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
    Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
    Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
    Hsu EC; Rice MA; Bermudez A; Marques FJG; Aslan M; Liu S; Ghoochani A; Zhang CA; Chen YS; Zlitni A; Kumar S; Nolley R; Habte F; Shen M; Koul K; Peehl DM; Zoubeidi A; Gambhir SS; Kunder CA; Pitteri SJ; Brooks JD; Stoyanova T
    Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2032-2042. PubMed ID: 31932422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.